DE69133068D1 - Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen - Google Patents

Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen

Info

Publication number
DE69133068D1
DE69133068D1 DE69133068T DE69133068T DE69133068D1 DE 69133068 D1 DE69133068 D1 DE 69133068D1 DE 69133068 T DE69133068 T DE 69133068T DE 69133068 T DE69133068 T DE 69133068T DE 69133068 D1 DE69133068 D1 DE 69133068D1
Authority
DE
Germany
Prior art keywords
enterotoxins
related compounds
destroying effects
tumor destroying
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69133068T
Other languages
English (en)
Other versions
DE69133068T2 (de
Inventor
David S Terman
Jay L Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23852299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69133068(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69133068D1 publication Critical patent/DE69133068D1/de
Publication of DE69133068T2 publication Critical patent/DE69133068T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464821—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464822—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69133068T 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen Revoked DE69133068T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46657790A 1990-01-17 1990-01-17
PCT/US1991/000342 WO1991010680A1 (en) 1990-01-17 1991-01-17 Tumor killing effects of enterotoxins and related compounds

Publications (2)

Publication Number Publication Date
DE69133068D1 true DE69133068D1 (de) 2002-08-22
DE69133068T2 DE69133068T2 (de) 2003-03-13

Family

ID=23852299

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69133484T Expired - Fee Related DE69133484T2 (de) 1990-01-17 1991-01-17 Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
DE69133485T Expired - Lifetime DE69133485T2 (de) 1990-01-17 1991-01-17 Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
DE69133068T Revoked DE69133068T2 (de) 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69133484T Expired - Fee Related DE69133484T2 (de) 1990-01-17 1991-01-17 Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
DE69133485T Expired - Lifetime DE69133485T2 (de) 1990-01-17 1991-01-17 Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie

Country Status (5)

Country Link
EP (3) EP1103268B1 (de)
AT (3) ATE220688T1 (de)
CA (1) CA2078003C (de)
DE (3) DE69133484T2 (de)
WO (1) WO1991010680A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
SE8903100D0 (sv) † 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5529934A (en) * 1991-07-29 1996-06-25 Biomide Investment Limited Partnership Method for measuring blood procoagulant activity of human leukocyte antigens
EP0626805A4 (en) * 1992-01-28 1995-12-06 Nat Jewish Ct Immun & Respirat Protective effects of mutated superantigens.
AU6358994A (en) * 1993-03-02 1994-09-26 David S. Terman Method of cancer treatment
US5585465A (en) * 1993-04-05 1996-12-17 National Jewish Center For Immunology And Respiratory Medicine Isolated toxin associated with Kawasaki syndrome
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US6075119A (en) 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
EP1127132A1 (de) * 1998-10-07 2001-08-29 The Rockefeller University Geeignete peptide zur reduzierung des toxischen schock syndroms und von septischem schock
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500905A (ja) * 1986-10-16 1989-03-30 プレジデント　アンド　フェロース　オブ　ハーバード　カレッジ 腫瘍壊死因子と抗炎症剤との組合せおよび悪性腫瘍性および非悪性腫瘍性疾患の処置方法
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent

Also Published As

Publication number Publication date
DE69133068T2 (de) 2003-03-13
DE69133485D1 (de) 2005-10-20
EP1129717A1 (de) 2001-09-05
EP0511306B1 (de) 2002-07-17
DE69133485T2 (de) 2006-06-22
CA2078003C (en) 2006-11-21
CA2078003A1 (en) 1991-07-18
DE69133484T2 (de) 2006-05-18
ATE304371T1 (de) 2005-09-15
EP0511306A1 (de) 1992-11-04
EP1129717B1 (de) 2005-09-14
DE69133484D1 (de) 2005-10-06
ATE220688T1 (de) 2002-08-15
EP1129717B2 (de) 2013-03-06
EP1103268B1 (de) 2005-08-31
EP1103268A1 (de) 2001-05-30
WO1991010680A1 (en) 1991-07-25
ATE303157T1 (de) 2005-09-15
EP0511306A4 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
DE69133068T2 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
BG101118A (en) Therapeutical compounds
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
NO893769L (no) Fremgangsmaate for behandling av naturgass.
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
NO910340D0 (no) Topiske preparater for behandling av menneskenegler.
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
DK0648503T3 (da) Pro-prodrugs, deres fremstilling og anvendelse
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
DK465488D0 (da) Farmaceutisk praeparat indeholdende en triazol-forbindelse
DE69127334D1 (de) Verabreichung von Mitteln
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
NO911429L (no) Stoffbehandling.
ES2159287T3 (es) Peptidos hemorreguladores.
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
DE59107762D1 (de) Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
RU95120677A (ru) Способ лечения злокачественных опухолей
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
ATE18132T1 (de) Pharmazeutische praeparate zur behandlung von nagelentzuendungen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation